Literature DB >> 22246419

Different clinical presentation of the hyperimmunoglobulin D syndrome (HIDS) (four cases from Turkey).

Dıdem Arslan Tas1, Suzan Dınkcı, Eren Erken.   

Abstract

Hyperimmunoglobulin D syndrome (HIDS) is one of the autoinflammatory syndromes which are characterized by febrile attacks. Duration and frequency of the febrile attacks, as well as typical organ involvements vary greatly. Recently, it is possible to reach more reliable data by the possibilities that are opened up by molecular genetics in order to highlight the aetiopathogenesis of this group of diseases. Typical patients with HIDS have an onset of disease in the first year of life. Here, we report four Turkish HIDS cases; three of whom, the symptoms started at a later age. The diagnoses were made by relevant clinical symptoms along with MVK mutations detected by DNA sequencing method. As summarised in this article, HIDS could be presented with a broad spectrum of symptoms. Although most of the HIDS patients are reported from Europe and especially Dutch ancestry, case reports are presented from all over the world. For this reason, HIDS should be kept in mind for the differential diagnosis of periodic fever syndromes or before accepting an FMF patient as colchichine resistant. We suppose that the phenomenon of "later-onset HIDS" should shed light into unresolved clinical problems of patients with periodic fever. Especially in countries that FMF is more frequent such as Turkey, even though the symptoms start later than classic cases, HIDS should be kept in mind for differential diagnosis of periodic fever syndromes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246419     DOI: 10.1007/s10067-011-1932-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  Hyperimmunoglobulinaemia D and periodic fever mimicking familial Mediterranean fever in the Mediterranean.

Authors:  R Topaloğlu; U Saatçi
Journal:  Postgrad Med J       Date:  1991-05       Impact factor: 2.401

2.  Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease?

Authors:  Rainer Siewert; Jörg Ferber; Rolf Dieter Horstmann; Christof Specker; Peter Julius Heering; Christian Timmann
Journal:  Am J Kidney Dis       Date:  2006-09       Impact factor: 8.860

3.  Hyperimmunoglobulinaemia D and periodic fever: a new syndrome.

Authors:  J W van der Meer; J M Vossen; J Radl; J A van Nieuwkoop; C J Meyer; S Lobatto; R van Furth
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

4.  Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome.

Authors:  Hiba M Shendi; Deirdre Walsh; J David M Edgar
Journal:  Rheumatol Int       Date:  2009-12-18       Impact factor: 2.631

5.  [Periodic fever: the first Portuguese case-report of hyper-IgD syndrome (HIDS)].

Authors:  Tiago Tribolet de Abreu
Journal:  Acta Med Port       Date:  2004-12-20

6.  MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever.

Authors:  Andrea D'Osualdo; Paolo Picco; Francesco Caroli; Marco Gattorno; Raffaella Giacchino; Patrizia Fortini; Fabrizia Corona; Alberto Tommasini; Giuseppe Salvi; Fernando Specchia; Laura Obici; Antonella Meini; Antonio Ricci; Marco Seri; Roberto Ravazzolo; Alberto Martini; Isabella Ceccherini
Journal:  Eur J Hum Genet       Date:  2005-03       Impact factor: 4.246

Review 7.  Mevalonate kinase deficiency and Dutch type periodic fever.

Authors:  J Frenkel; S M Houten; H R Waterham; R J Wanders; G T Rijkers; J L Kimpen; R Duran; B T Poll-The; W Kuis
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

8.  Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome.

Authors:  Jeroen C H van der Hilst; Evelien J Bodar; Karyl S Barron; Joost Frenkel; Joost P H Drenth; Jos W M van der Meer; Anna Simon
Journal:  Medicine (Baltimore)       Date:  2008-11       Impact factor: 1.889

9.  Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum.

Authors:  Viola Prietsch; Ertan Mayatepek; Hermann Krastel; Dorothea Haas; Dorothee Zundel; Hans R Waterham; Ronald J A Wanders; K Michael Gibson; Georg F Hoffmann
Journal:  Pediatrics       Date:  2003-02       Impact factor: 7.124

10.  A patient with hyper-IgD syndrome in Antalya, Turkey.

Authors:  Erkan Coban; Ender Terzioğlu
Journal:  Clin Rheumatol       Date:  2004-02-24       Impact factor: 2.980

View more
  3 in total

1.  The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.

Authors:  Micol Romano; Z Serap Arici; David Piskin; Sara Alehashemi; Daniel Aletaha; Karyl Barron; Susanne Benseler; Roberta A Berard; Lori Broderick; Fatma Dedeoglu; Michelle Diebold; Karen Durrant; Polly Ferguson; Dirk Foell; Jonathan S Hausmann; Olcay Y Jones; Daniel Kastner; Helen J Lachmann; Ronald M Laxer; Dorelia Rivera; Nicola Ruperto; Anna Simon; Marinka Twilt; Joost Frenkel; Hal M Hoffman; Adriana A de Jesus; Jasmin B Kuemmerle-Deschner; Seza Ozen; Marco Gattorno; Raphaela Goldbach-Mansky; Erkan Demirkaya
Journal:  Arthritis Rheumatol       Date:  2022-05-27       Impact factor: 15.483

2.  Hyperimmunoglobulinaemia D syndrome: a rare cause of prolonged fever and treatment with anti-interleukin 1 agent.

Authors:  Deniz Aygun; Sezgin Sahin; Haluk Cokugras; Ozgur Kasapcopur
Journal:  BMJ Case Rep       Date:  2016-05-17

3.  Genetic Landscape of Rare Autoinflammatory Disease Variants in Qatar and Middle Eastern Populations Through the Integration of Whole-Genome and Exome Datasets.

Authors:  Parul Sharma; Abhinav Jain; Vinod Scaria
Journal:  Front Genet       Date:  2021-05-13       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.